Lang et al. at University of Tübingen in Germany also investigated CD3-/CD19- haploidentical PBSC using a melphalan-based non-TBI RIC regimen in pediatric patients with hematologic malignancies treated between 2004 and 2012. The gene discussed is CD19; the disease is hematologic disorder.